Brexogen, a biotechnology company specializing in exosome-based therapeutics, has signed a technology transfer and licensing agreement with BMI Korea. This agreement marks the first major licensing deal for an exosome therapeutic in Korea, highlighting the growing interest and potential of exosome-based medicines in the region. BxC-I17e, a key asset in Brexogen’s pipeline, is currently undergoing clinical trials in the United States for atopic dermatitis. Recognizing its broader therapeutic p...